Biosynthesis and Packaging of Carboxypeptidase D into Nascent Secretory Vesicles in Pituitary Cell Lines*

Oleg VarlamovDagger , Fang Wu§, Dennis Shields§, and Lloyd D. FrickerDagger

From the Dagger  Department of Molecular Pharmacology and the § Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, New York 10461

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Metallocarboxypeptidase D (CPD) is a membrane-bound trans-Golgi network (TGN) protein. In AtT-20 cells, CPD is initially produced as a 170-kDa endoglycosidase H-sensitive glycoprotein. Within 30 min of chase, the CPD increases to 180 kDa and is resistant to endoglycosidase H as a result of carbohydrate maturation. CPD also undergoes an activation step required for binding to a substrate affinity resin. Blocking the protein exit from the endoplasmic reticulum inhibits the increase in molecular mass but not the step required for affinity column binding, suggesting that enzyme activation precedes carbohydrate maturation and that these reactions occur in distinct intracellular compartments. Only the higher molecular weight mature CPD enters nascent secretory vesicles, which bud from the TGN of permeabilized AtT-20 and GH3 cells. The budding efficiency of CPD into vesicles is 2-3-fold lower than that of endogenous proopiomelanocortin in AtT-20 cells or prolactin in GH3 cells. In contrast, the packaging of a truncated form of CPD, which lacks the cytoplasmic tail and transmembrane domain, was similar to that of proopiomelanocortin. Taken together, the results support the proposal that CPD functions in the TGN in the processing of proteins that transit the secretory pathway and that the C-terminal region plays a major role in TGN retention.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Many bioactive peptides are synthesized from larger proteins by proteolytic processing that occurs in different organelles. Several endoproteases, which cleave at basic amino acid containing sites, have been described: prohormone convertase-1 (PC1)1 (also known as PC3), PC2, PC4, PACE4, PC5A and -B (also known as PC6A and -B), and PC7 (also known as PC8 and LPC) (1-6). Following the endoprotease step, a carboxypeptidase is usually required to remove residual Lys and/or Arg residues from the C terminus of the peptide (7, 8). In some cases, further modification results in a C-terminal amide residue; this reaction is catalyzed by the enzyme peptidylglycine alpha -amidating monooxygenase (9).

Until recently, carboxypeptidase E (CPE, also known as carboxypeptidase H, enkephalin convertase, and E.C. 3.4.17.10) was thought to be the only carboxypeptidase involved in the generation of peptide hormones and neurotransmitters (7, 8). However, studies on Cpefat/Cpefat mice have suggested that another carboxypeptidase contributes to peptide processing in addition to CPE (10). The Cpefat/Cpefat mice have a point mutation in the coding region of the CPE gene, which inactivates the enzyme resulting in its degradation prior to secretion (10, 11). These mice have reduced levels of several peptide hormones and neurotransmitters and elevated levels of proteolytic-processing intermediates containing C-terminal basic residues (10, 12, 13); this finding is strong evidence that CPE plays a major role in peptide processing. However, fully processed peptides are present in moderate levels in Cpefat/Cpefat mice, raising the possibility that another carboxypeptidase contributes to peptide processing.

Carboxypeptidase D (CPD) was discovered during a recent search for enzymes with carboxypeptidase-like enzymatic properties (14). Both CPE and CPD have substantial activity at pH values in the 5-6 range (14), which is consistent with the internal pH of the intracellular compartments where processing is thought to occur (15, 16). However, the intracellular localization of CPE and CPD differ; CPE is predominantly in the secretory vesicles of the regulated pathway, whereas CPD is enriched in the TGN and immature secretory granules (17, 18). The physical properties of the two enzymes are also different. CPE is a 50-56-kDa protein that is present both as a soluble and peripheral membrane-associated form, whereas CPD is a type I 180-kDa transmembrane glycoprotein (14). Recently, rat (19) and human (20) CPD cDNAs have been sequenced and were found to be homologs of duck gp180, a protein that binds duck hepatitis B virus particles (21). Duck gp180 and rat and human CPD contain three repeats of a 50-kDa CPE-like domain, followed by a transmembrane domain and a 58 residue cytosolic tail (19-21). Several other enzymes in the secretory pathway are also membrane-bound proteins, such as furin, PC5B, and peptidylglycine alpha -amidating monooxygenase (22-24). These membrane-bound proteins are located in the TGN, although they also cycle to the cell surface (25, 26).

The purpose of the present study was to examine the biosynthesis and sorting of endogenous CPD into nascent secretory vesicles in the AtT-20 and GH3 cell lines. These cells express CPD mRNA (19) and have been extensively used to study the biosynthesis and intracellular trafficking of peptide hormones and processing enzymes. The results of the pulse-chase analysis in the present study are consistent with the previous finding that CPD is present in the TGN and cycles from the cell surface back to the TGN (17) in AtT-20 cells. In addition, the finding that newly synthesized CPD is able to enter nascent secretory vesicles that bud from the TGN, albeit at a reduced efficiency relative to endogenous prohormones and hormones, is further evidence that CPD functions in the TGN and immature secretory vesicles in the processing of peptides and proteins. Our results also demonstrate that the cytoplasmic tail and/or transmembrane domain of CPD play an essential role in retaining the enzyme in the TGN.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Pulse-Chase Analysis-- Wild type AtT-20 cells in 60-mm plates were incubated for 1 h in Dulbecco's modified Eagle's medium lacking methionine and then radiolabeled (pulsed) with [35S]Met for 15 min, washed 3 times with media, and chased for various times at 37 °C. In some experiments, the chase was performed in media containing brefeldin A (5 µg/ml), cycloheximide (100 µg/ml), or at 15 or 20 °C. Following the chase, the media were removed, and the cells were washed once with phosphate-buffered saline. Cells were then frozen on dry ice after adding 0.5 ml of 10 mM NaAc buffer at pH 5.5.

For the analysis of the active form of CPD, the cells were thawed and sonicated, and the buffer was adjusted to 1% Triton X-100 and 1 M NaCl in 50 mM NaAc, pH 5.5. The homogenate was centrifuged at 30,000 × g for 30 min, and the supernatant was subjected to purification on a 0.5-ml p-aminobenzoylarginine-Sepharose 6B affinity column as described (14, 27). Cell medium was also analyzed on the affinity resin after first adjusting the pH to 5.5 with 50 mM NaAc. CPD was eluted from the affinity column using 2 ml of Tris buffer, pH 8, containing 50 mM NaCl, 25 mM Arg, and 0.01% Triton X-100. Aliquots of the affinity column eluate were analyzed on a 8% denaturing polyacrylamide gel, which was then treated with Fluoro-hance and exposed to x-ray film (Kodak). Quantitation of autoradiograms was performed using an image analysis system as described (28). All autoradiograms used for quantitation were in the linear range of the system.

For the isolation of CPD and CPE by immunoprecipitation, aliquots of the extracts described above were used. In some experiments, cells were extracted directly with 2% SDS using the standard immunoprecipitation protocol (29). Immunoprecipitation was performed using polyclonal antisera against purified rat CPD, purified duck CPD (gp180), the C-terminal 57 residues of duck CPD, or the C-terminal 9 residues of rat CPE (11, 27). Antisera-bound CPD was isolated using protein A-Sepharose 4B beads (Sigma) as described (29). CPD was recovered by boiling the protein A-Sepharose 4B pellet in polyacrylamide gel-loading buffer containing 1% SDS for 5 min, and the immunoprecipitated material was analyzed on denaturing 6% polyacrylamide gels as described above. In some experiments, the immunoprecipitated material was incubated in the presence of N-glycosidase F (New England Biolabs), endoglycosidase H (New England Biolabs), or neuraminidase from Vibrio cholerae (Roche Molecular Biochemicals) for 16 h at 37 °C. Prior to incubation with the protease-free glycosidases, the samples were boiled to inactivate any contaminating proteases. Following digestion, the samples were analyzed on denaturing polyacrylamide gels as described above.

Permeabilized Cell Preparation and in Vitro Incubations-- The preparation of permeabilized cells by a swell-scrape method was described previously (30, 31). Basically, cells were radiolabeled for 10 min with [35S]Met, chased for 120 min (or shorter times) at 20 °C, and incubated in cold hypotonic buffer (15 mM KCl, 10 mM HEPES, pH 7.2) for 5 min. After swelling, the cells were scraped off the plate with a rubber policeman and resuspended in 90 mM KCl, 10 mM HEPES, pH 7.2, and 1 mM MgCl2, as described (30, 31). Cells used for these analyses included wild type GH3 cells, AtT-20 cells expressing gp180 (18), and AtT-20 cells expressing gp180Delta C-term, a truncated form of duck CPD that lacks the cytosolic tail and transmembrane region.2 The incubation conditions for these experiments consisted of approximately 5 × 105 permeabilized cells, 20 mM HEPES, pH 7.3, 125 mM KCl, 2.5 mM MgCl2, 1 mM ATP, 200 µM GTP, 10 mM creatinine phosphate, 160 µg/ml creatinine phosphate kinase (ATP-regenerating system), 0.5 mM phenylmethylsulfonyl fluoride, and 5 µg/ml Trasylol. Incubation for 90 min at 37 °C under these conditions is sufficient to reconstitute both prohormone processing and nascent secretory vesicle release from the TGN (30, 31).

The assay for nascent secretory vesicle budding was based on quantitating the release of radiolabeled hormones into a 15,000 × g supernatant following an in vitro incubation (31, 33). Following the incubation, permeabilized cells were pelleted and lysed in detergent, and the lysates and supernatants containing nascent secretory vesicles were immunoprecipitated with antisera to either rat CPD, duck CPD (gp180), CPE, prolactin, or ACTH (a gift of Dr. Richard Mains, Johns Hopkins University) (this antiserum also recognizes proopiomelanocortin and intermediate processing forms of ACTH) as described (31). Immunoreactive material was resolved by SDS-polyacrylamide gel electrophoresis and detected by fluorography. Band intensities were quantitated using a Molecular Dynamics model 300A computing densitometer and Image Quant 3.3 software (Molecular Dynamics, Sunnyvale, CA).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The biosynthesis of CPD was investigated in AtT-20 cells using metabolic labeling with [35S]Met and two techniques to isolate the radiolabeled CPD, substrate affinity chromatography and immunoprecipitation. After a 15-min pulse with radiolabel followed by purification of the CPD on a substrate affinity resin, a single 170-kDa form of CPD was detected (Fig. 1). During the 30 min chase period, the apparent molecular mass of the radiolabeled CPD increased to 180 kDa, and the amount of radiolabeled CPD recovered from the affinity column also increased severalfold (Fig. 1). Quantitation of the results from four separate experiments showed a reproducible 3-fold increase in the amount of affinity-purified radiolabeled CPD upon early chase times (Fig. 2). Following this increase, the level of radiolabeled CPD remained constant for several hours and then decreased (Figs. 1 and 2). After 20 h, the cellular level of radiolabeled CPD was approximately 30% of the peak value. No radiolabeled CPD was detected in the media for any of the time points investigated (Fig. 1).


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 1.   Pulse-chase analysis of CPD in AtT-20 cells. Cells were pulsed for 15 min, chased for the indicated period of time, and extracted as described under "Materials and Methods." Equal proportions of cell extracts and media were subjected to purification on a p-aminobenzoyl- arginine-Sepharose 6B affinity column, and the column eluates were fractionated on a denaturing 8% polyacrylamide gel. The positions of prestained size standards (Bio-Rad) are indicated.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 2.   Quantitation of the pulse-chase analysis of CPD and CPE in AtT-20 cells upon purification by substrate affinity column. Quantitation was performed using exposures within the linear range of the film. The levels of each carboxypeptidase are relative to the maximal level for that protein and are not relative to each other. Error bars show the standard error of the mean for n = 4. Data points without error bars had standard error smaller than the symbol size. CP, carboxypeptidase.

To compare the relative amount of CPE and CPD produced by the same cells, the affinity columns were first eluted with high pH buffer (to elute CPE) before eluting the CPD with Arg. Analysis of the CPE-containing fractions showed a major band of approximately 55 kDa (not shown). The intensity of this band was substantially greater than that of the radiolabeled CPD. Because the affinity columns appear to bind both proteins quantitatively, the AtT-20 cells synthesize approximately 50-100-fold more CPE than CPD, after adjustment for the number of Met residues in each protein. Quantitation of the radiolabeled CPE from four separate experiments showed a 35% decrease over the first hour followed by a slower decrease over the remainder of the chase period (Fig. 2). As previously reported (34), radiolabeled CPE was detected in the media after 1 h of chase and accumulated with increasing chase time (not shown).

When the radiolabeled CPD in the pulse-chase extracts was isolated by immunoprecipitation, its apparent molecular mass increased from 170 to 180 kDa during the 1 h chase period, but no increase in the amount of radiolabeled protein was evident (Fig. 3). Similar results were obtained when using antiserum raised against either the mature form of rat CPD (Fig. 3) or against its C-terminal region (data not shown). No differences in gel mobility were detected in comparing the extraction procedures used for the affinity column procedure (Triton X-100 plus NaCl) with the procedure used for immunoprecipitation (SDS) (data not shown). Thus, the increase in the amount of radiolabeled CPD recovered from the affinity column with time presumably represents an activation step, possibly protein folding, that is required for binding to the substrate affinity resin. In contrast to the increase in radiolabeled CPD seen during short chase periods with the affinity purification method, the decrease in CPD levels upon long chase periods was comparable for both the affinity purification and immunoprecipitation, indicating that the reduction is because of loss of CPD protein and not because of less efficient binding to the affinity column (not shown).


View larger version (45K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of glycosidase treatment on the apparent molecular mass of CPD. AtT-20 cells were pulsed for 15 min and chased for the indicated time. The cellular CPD was isolated by immunoprecipitation and aliquots were treated with neuraminidase (Neura.), N-glycosidase F (N-glyc-F), or endoglycosidase H (Endo-H). The positions of prestained size standards (Bio-Rad) are indicated.

To investigate whether changes in glycosylation contributed to the increase in apparent molecular mass of CPD, affinity purified material was treated with glycosidases. N-Glycosidase F, which removes all N-linked sugars, reduced the size of the protein isolated immediately after the pulse (i.e. the 170-kDa form) to 147 kDa and the form after chase (i.e. the 180-kDa form) to 150 kDa (Fig. 3). Neuraminidase digestion, which removes terminal sialic acid, decreased the apparent molecular mass of the 180-kDa species to 175 kDa but had no effect on the migration of the 170-kDa form (Fig. 3). This finding indicates that only the 180-kDa form had reached the trans-Golgi (the site of sialyltransferase activity) during 1 h of chase. Endoglycosidase H reduced the apparent molecular mass of the 170-kDa species to 147 kDa but had no effect on the 180-kDa form (Fig. 3). Thus, the 170-kDa species is endoglycosidase H sensitive, although the 180-kDa form is endoglycosidase H resistant, suggesting that the smaller form is predominantly localized to the ER or cis-Golgi, whereas the larger species is present in the medial or trans-Golgi.

To further study the biosynthesis of CPD, the pulse-chase was performed under several conditions that trap proteins in the ER followed by isolation using a substrate affinity resin (Fig. 4). To test whether the increase in the amount of CPD recovered on the affinity resin was because of increased synthesis of CPD, cycloheximide was used. When cycloheximide was added to the chase medium to block further protein synthesis, the amount and size of CPD was identical to that isolated from control untreated cells (Figs. 4 and 5, X). Brefeldin A added during the chase prevented the increase in apparent molecular mass but not the amount of CPD recovered from the affinity resin (Figs. 4 and 5, B). Similarly, when the chase was performed at 15 °C, the increase in size was prevented but not the amount of radiolabeled CPD bound to the affinity resin (Figs. 4 and 5, 15). Incubation at 20 °C, which prevents the exit of vesicles from the trans-Golgi network (30, 35), partially blocked the size increase (Figs. 4 and 5, 20). Taken together, these results suggest that the activation step is an ER event because treatments that block the exit from the ER do not prevent the activation.


View larger version (64K):
[in this window]
[in a new window]
 
Fig. 4.   Pulse-chase analysis of CPD in AtT-20 cells. Cell were pulsed for 15 min and then either analyzed directly or chased for 1 h in control media at 37 °C or in the presence of cycloheximide (X) (100 µg/ml), brefeldin A (B) (5 µg/ml), or in control media at 15 (15) or 20 °C (20). CPD was isolated from the cells by the affinity column procedure as described under "Materials and Methods." The positions of prestained size standards (Bio-Rad) are indicated.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 5.   Quantitation of the effect of various conditions on the amount of [35S]Met-labeled CPD recovered from the affinity resin. Error bars indicate standard error of the mean, n = 3. Statistical significance was determined using Student's t test: *, p < 0.05; **, p < 0.01 compared with the "no chase" sample. X, cycloheximide; B, brefeldin A; 15, 15 °C; 20, 20 °C.

To determine if CPD is packaged into nascent secretory vesicles, a permeabilized cell assay was used. This involves pulse-labeling the cells with [35S]Met followed by a 2 h chase at 20 °C to trap the radiolabeled proteins in the TGN, followed by permeabilization of the cells and analysis of the proteins present in nascent secretory vesicles, which are released from the TGN during subsequent in vitro incubation at 37 °C (31). For these experiments, AtT-20 cells were used as well as the rat anterior pituitary GH3 cell line because preliminary data determined these cells have relatively high levels of CPD. In addition, permeabilized GH3 cells have been used extensively to investigate vesicle budding from the TGN (36) and vesicle fusion with the plasma membrane (37). In GH3 cells, newly synthesized CPD was approximately 170 kDa (Fig. 6A, lane 1). When the cells were chased for 2 h at 20 °C, the majority of the protein remained as the 170-kDa form, although a small amount was present as a 180-kDa protein (Fig. 6A, lane 2). Only the larger form of CPD entered nascent secretory vesicles (Fig. 6A, lane 6). Release of the vesicles from the TGN and the packaging of the 180-kDa CPD was dependent on the presence of an energy-generating system (compare lanes 6 and 8).


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 6.   Packaging of CPD into nascent secretory vesicles in pituitary AtT-20 and GH3 cells. A-D, wild type GH3 cells (A and C) or AtT-20 cells expressing gp180 (B and D) were incubated with [35S]Met at 37 °C for 10 min (A and B, lane 1) and chased at 20 °C for 2 h (A and B, lane 2). To assay for nascent secretory vesicle budding, cells were pulse-labeled with [35S]Met and chased at 20 °C for 2 h to accumulate radiolabeled proteins in the TGN, after which the cells were permeabilized as described under "Materials and Methods." Permeabilized cells were incubated in the presence or absence of an energy-generating system for the indicated time. Following incubation, the samples were centrifuged at 15,000 × g for 30 s to generate a pellet (P) containing TGN and other organelles and supernatant (S) containing nascent secretory vesicles. Each fraction was then treated sequentially with rabbit antiserum to rat CPD (A) or duck CPD (B) followed by antiserum to PRL (C) or ACTH (D), and the immunoprecipitated material was resolved by SDS-polyacrylamide gel electrophoresis. E, AtT-20 cells expressing gp180 were radiolabeled with [35S]Met for 10 min and chased at 20 °C for 30 (lanes 1-4) or 60 min (lanes 5-8). Cells were permeabilized, and vesicle budding was performed for 90 min at 37 °C in the presence or absence of the energy-generating system (EGS) as indicated.

When wild type AtT-20 cells were used, the level of endogenous CPD was not easily detected in the budded vesicles, and so a cell line overexpressing duck CPD (gp180) was used. In these cells, the processing of CPD from the 170 to the 180-kDa species was much more efficient than in GH3 cells, and only a small fraction of the enzyme remained 170 kDa following a 2 h chase at 20 °C (Fig. 6B, lane 2). For both AtT-20 and GH3 cell lines, the relative amount of CPD that entered into the nascent secretory vesicles represented only a small fraction (12-14%) (Table I) of the total radiolabeled CPD. In contrast, the budding of nascent secretory vesicles containing prolactin (PRL) from the TGN of GH3 cells or of proopiomelanocortin (POMC) from AtT-20 cells was significantly more efficient (36-41%) (Table I) and was similar to results previously obtained (30, 31). As expected the budding of vesicles containing these prohormones was energy-dependent (30, 38) (Fig. 6, C and D). The low apparent budding efficiency of CPD into nascent secretory vesicles was not because of the intrinsic inefficiency of the permeabilized system, because vesicles containing soluble cargo polypeptides (PRL and POMC) were efficiently released from the TGN (Table I).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Quantitation of vesicle budding

To test whether the 170-kDa form of CPD detected after short chase times in AtT-20 cells was unable to enter secretory vesicles as found for the CPD in GH3 cells, the vesicle budding assay was performed on cells that had been chased for only 30 or 60 min at 20 °C prior to generating a permeabilized cell preparation. For these experiments, cells expressing duck CPD (gp180) were used to improve the signal in the budding assay. After 60 min of chase at 20 °C, both 170- and 180-kDa forms of duck CPD were detected (Fig. 6E, lanes 5-8), which is consistent with the results with endogenous CPD in AtT-20 cells (Figs. 1, 3, and 4) and endogenous CPD in GH3 cells (Fig. 6A). The mature 180-kDa form of duck CPD in AtT-20 cells entered the nascent vesicles more efficiently than the immature 170-kDa form (Fig. 6E, lane 8). When the cells were chased for 30 min at 20 °C prior to permeabilization and vesicle budding, the 170-kDa form of CPD was predominant (Fig. 6E, lanes 1-4). Although only small amounts of the 180-kDa form were detected at this early chase time, the relative amount of this form in the nascent vesicles was greater than the 170-kDa form. Very low levels of the 170-kDa form of duck CPD were detected in budded vesicles after 30 min of chase at 20 °C (Fig. 6E, lane 4). It is possible that the vesicles that contain the 170-kDa form at the early chase times were derived in part from the ER or early Golgi compartments.

We hypothesized that the inefficient budding of CPD was a consequence of its retention in the TGN mediated by its C-terminal region. To test this idea, permeabilized AtT-20 cells were prepared from a cell line expressing gp180Delta C-term, a truncated form of CPD, which lacks the cytoplasmic tail and membrane anchor (Fig. 7). Significantly, the budding of vesicles containing gp180Delta C-term was generally similar to that of POMC and CPE (Table I), suggesting that the C-terminal region (cytoplasmic tail and/or transmembrane domain) of CPD functions in part as a retention sequence to decrease the efficiency of CPD packaging into nascent vesicles.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 7.   A C-terminally truncated form of duck CPD (gp180Delta C-term) enters nascent secretory vesicles more efficiently than gp180. Top, schematic representation of gp180 and gp180Delta C-term. gp180Delta C-term contains residues 1-1307 of gp180 and lacks the transmembrane domain (TM) and cytoplasmic tail. Bottom, stable AtT-20 cell lines expressing gp180 or gp180Delta C-term were pulse-labeled with [35S]Met and chased for 2 h at 20 °C as outlined in Fig. 6 and under "Materials and Methods." The permeabilized cells were incubated for 90 min at 37 °C in the absence (lanes 1, 2, 5, and 6) or presence (lanes 3, 4, 7, and 8) of an energy-generating system. Following incubation, nascent secretory vesicles (S) were separated from residual permeabilized cells (P) by brief centrifugation, and the pellets and supernatant fractions were immunoprecipitated with rabbit antiserum to the N-terminal region of duck CPD (gp180). The immunoprecipitable material was resolved by SDS-polyacrylamide gel electrophoresis as described under "Materials and Methods." EGS, energy-generating system.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

A major finding of the present study is that the turnover of CPD and CPE are substantially different in AtT-20 cells. This difference presumably reflects the intracellular location of each enzyme. CPD is an integral membrane protein that is predominantly localized to the TGN (17), whereas CPE is present in secretory vesicles as soluble and peripheral membrane-associated forms (7, 8). In addition, CPD recycles from the cell surface (17) and is not secreted into the media (Fig. 1), whereas CPE is secreted via the regulated secretory pathway (7, 8). These differences are likely to be responsible for the observed differences in the turn-over rate for the two enzymes.

The large increase in the amount of radiolabeled CPD detected during the 1 h chase period, as determined by binding to a substrate affinity resin (Fig. 1), was not observed when the CPD was isolated by immunoprecipitation (Fig. 3) indicating that CPD requires an activation step for binding to the affinity resin. Although most peptide-processing endopeptidases are initially produced as inactive precursors that require cleavage of a propeptide for activation (39), peptide-processing carboxypeptidases do not typically require proteolytic activation. For example, proCPE and CPE are both enzymatically active (40, 41). It is unlikely that CPD undergoes proteolytic activation because the N terminus of the active form of CPD corresponds to the sequence immediately downstream of the signal peptide cleavage site (19, 20). Also, the activation step does not correlate with the increase in apparent molecular weight that also occurs during the first 30-60 min of synthesis. Furthermore, brefeldin A or incubation at 15 °C blocked the increase in size but had no effect on the amount of CPD bound to the affinity resin (Fig. 4). These observations suggest that the activation step occurs in the ER. Because the activation of CPD does not substantially alter the size of the protein, it is likely that this activation reflects the folding of the CPD into a conformation that is able to bind to the substrate affinity resin.

The increase in the apparent molecular weight of CPD that occurs approximately 30 min after protein synthesis appears to result from changes in glycosylation, because the mobility of CPD on SDS-polyacrylamide gel electrophoresis is increased upon the removal of N-linked carbohydrates (Fig. 3). It is likely that the modification of CPD leading to the shift in apparent molecular mass from 170 to 180 kDa occurs in the TGN because it is blocked by either brefeldin A or incubation at 15 but not 20 °C (Figs. 4 and 6). Brefeldin A causes the collapse of the Golgi apparatus, the redistribution of Golgi proteins into the ER (42), and blocks protein transport to the TGN (43). Incubation at 15 °C also blocks the exit of proteins from the ER, whereas incubation at 20 °C blocks the exit from the TGN (30, 35). The partial effect of the 1-h chase at 20 °C (Fig. 4) on the size shift of CPD in the AtT-20 cells is presumably because of incomplete transport of this protein to the TGN at the reduced temperature; when the chase was performed for 2 h at 20 °C, the majority of the CPD was present in the larger 180-kDa form (Fig. 6). Taken together, it is likely that the increase in size of CPD largely, but not entirely, results from the addition of terminal sialic acid residues, a modification that occurs in the late Golgi and/or TGN. The possibility of other modifications (such as sulfation and palmitoylation) cannot be excluded, although studies using chlorate to block sulfation and chemical treatments to remove palmitate did not provide any evidence for these modifications of CPD (data not shown).

Interestingly, only the larger form of CPD was found to enter nascent secretory vesicles that bud from the TGN (Fig. 6). There are several possible interpretations of this observation; either the lower molecular weight form is prevented from being packaged into nascent secretory vesicles or the enzymes that mediate the size increase are enriched or activated in the budded vesicles so that the processing occurs soon after budding. The former possibility is consistent with the size increase resulting from sialylation because sialyltransferases are present in the TGN. A similar result was observed with furin; only the higher molecular weight sialylated form was found to enter nascent vesicles that bud from the TGN (38).

The efficiency of the budding of CPD is similar in the two cell lines examined and is substantially lower than that of endogenous hormones. The difference in efficiency presumably reflects the distribution of the various proteins; although CPD is enriched in the TGN, peptide hormones are primarily located in the mature secretory vesicles of neuroendocrine cells. It is possible that the cytoplasmic tail and/or transmembrane region of CPD binds to cytoskeletal proteins, thus preventing the majority of the CPD from entering nascent secretory vesicles. We speculate that a small fraction of the CPD polypeptides are modified in the tail domain (possibly by phosphorylation or dephosphorylation) allowing them to be released and packaged into the budding vesicles along with the cargo molecules. In this context, it is noteworthy that the C-terminally truncated gp180Delta C-term CPD, which lacks both a cytoplasmic tail and transmembrane domain, was sorted into nascent vesicles with an efficiency similar to that of PRL or POMC (Fig. 7 and Table I). This finding suggests that the tail and/or transmembrane domain may play an important role in TGN retention as previously hypothesized from studies on the distribution of CPD C-terminal mutants in AtT-20 cells (18). Most significantly, these data demonstrate the specificity of the vesicle budding reaction and strongly suggest that the permeabilized cell system maintains significant selectively with respect to the packaging of cargo molecules into post-Golgi vesicles, which presumably includes both regulated and constitutive pathway vesicles. If packaging of cargo proteins were nonselective or vesicle release resulted from the random fragmentation of the Golgi apparatus/TGN in vitro, then it would be expected that similar levels of CPD and PRL or POMC would be present in the vesicle fraction; our data demonstrate that this is not the case.

The results of the present study, together with previous studies (17, 18), support the proposal that CPD functions in the TGN and/or immature secretory vesicles to process proteins that transit the secretory pathway. In this regard, CPD is similar to both furin and peptidylglycine alpha -amidating monooxygenase. All three enzymes contain large N-terminal lumenal domains, a transmembrane domain, and a short C-terminal cytoplasmic tail. Furin is primarily located in the TGN, although it also cycles to the cell surface and back to the TGN (25, 44). The membrane form of peptidylglycine alpha -amidating monooxygenase is also primarily present in the TGN, but smaller soluble forms of this protein are enriched in mature secretory granules (32). The long half-life of CPD in the pulse-chase analysis, the lack of detectable processing of CPD to shorter forms, and the absence of secretion of a significant portion of the CPD from AtT-20 cells are similar to the properties of furin. In addition, both furin (38) and CPD (Fig. 6) are detected in vesicles that bud from the TGN. Taken together, it is likely that CPD functions following the action of furin or another related endopeptidase.

    ACKNOWLEDGEMENTS

We gratefully acknowledged Dr. Lixin Song for performing some of the preliminary data on the pulse-chase analysis of CPD in the AtT-20 cells.

    FOOTNOTES

* This work was primarily supported by National Institutes of Health Grants R01 DK-51271 (to L. D. F.), K02 DA-00194 (to L. D. F.), and R37 DK21860 (to D. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Dept. of Molecular Pharmacology, Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, NY 10461. Tel.: 718-430-4225; Fax: 718-430-8954; E-mail: fricker{at}aecom.yu.edu.

2 Varlamov, O., Eng, F. J., Novikova, E. G., and Fricker, L. D. (1999) J. Biol. Chem., in press.

    ABBREVIATIONS

The abbreviations used are: PC, prohormone convertase; CPE, carboxypeptidase E; CPD, carboxypeptidase D; TGN, trans-Golgi network; ER, endoplasmic reticulum; PRL, prolactin; POMC, proopiomelanocortin; ACTH, adrenocorticotropic hormone.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
  1. Smeekens, S. P., and Steiner, D. F. (1990) J. Biol. Chem. 265, 2997-3000[Abstract/Free Full Text]
  2. Seidah, N. G., Gaspar, L., Mion, P., Marcinkiewicz, M., Mbikay, M., and Chretien, M. (1990) DNA Cell Biol. 9, 415-424[Medline] [Order article via Infotrieve]
  3. Hosaka, M., Nagahama, M., Kim, W. S., Watanabe, T., Hatsuzawa, K., Ikemizu, J., Murakami, K., and Nakayama, K. (1991) J. Biol. Chem. 266, 12127-12130[Abstract/Free Full Text]
  4. Kiefer, M. C., Tucker, J. E., Joh, R., Landsberg, K. E., Saltman, D., and Barr, P. J. (1991) DNA Cell Biol. 10, 757-769[Medline] [Order article via Infotrieve]
  5. Nakagawa, T., Hosaka, M., Torii, S., Watanabe, T., Murakami, K., and Nakayama, K. (1993) J. Biochem. (Tokyo) 113, 132-135[Abstract]
  6. Seidah, N. G., Hamelin, J., Mamarbachi, M., Dong, W., Tadros, H., Mbikay, M., Chretien, M., and Day, R. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 3388-3393[Abstract/Free Full Text]
  7. Fricker, L. D. (1988) Annu. Rev. Physiol. 50, 309-321[CrossRef][Medline] [Order article via Infotrieve]
  8. Fricker, L. D. (1991) in Peptide Biosynthesis and Processing (Fricker, L. D., ed), pp. 199-230, CRC Press, Boca Raton, FL
  9. Eipper, B. A., and Mains, R. E. (1988) Annu. Rev. Physiol. 50, 333-344[CrossRef][Medline] [Order article via Infotrieve]
  10. Naggert, J. K., Fricker, L. D., Varlamov, O., Nishina, P. M., Rouille, Y., Steiner, D. F., Carroll, R. J., Paigen, B. J., and Leiter, E. H. (1995) Nat. Genet. 10, 135-142[Medline] [Order article via Infotrieve]
  11. Varlamov, O., Leiter, E. H., and Fricker, L. D. (1996) J. Biol. Chem. 271, 13981-13986[Abstract/Free Full Text]
  12. Rovere, C., Viale, A., Nahon, J., and Kitabgi, P. (1996) Endocrinology 137, 2954-2958[Abstract]
  13. Fricker, L. D., Berman, Y. L., Leiter, E. H., and Devi, L. A. (1996) J. Biol. Chem. 271, 30619-30624[Abstract/Free Full Text]
  14. Song, L., and Fricker, L. D. (1995) J. Biol. Chem. 270, 25007-25013[Abstract/Free Full Text]
  15. Russell, J. T. (1984) J. Biol. Chem. 259, 9496-9507[Abstract/Free Full Text]
  16. Johnson, R. G., and Scarpa, A. (1976) J. Biol. Chem. 251, 2189-2191[Abstract]
  17. Varlamov, O., and Fricker, L. D. (1998) J. Cell Sci. 111, 877-885[Abstract/Free Full Text]
  18. Eng, F. J., Varlamov, O., and Fricker, L. D. (1999) Mol. Biol. Cell 10, 35-46[Abstract/Free Full Text]
  19. Xin, X., Varlamov, O., Day, R., Dong, W., Bridgett, M. M., Leiter, E. H., and Fricker, L. D. (1997) DNA Cell Biol. 16, 897-909[Medline] [Order article via Infotrieve]
  20. Tan, F., Rehli, M., Krause, S. W., and Skidgel, R. A. (1997) Biochem. J. 327, 81-87[Medline] [Order article via Infotrieve]
  21. Kuroki, K., Eng, F., Ishikawa, T., Turck, C., Harada, F., and Ganem, D. (1995) J. Biol. Chem. 270, 15022-15028[Abstract/Free Full Text]
  22. Hatsuzawa, K., Hosaka, M., Nakagawa, T., Nagase, M., Shoda, A., Murakami, K., and Nakayama, K. (1990) J. Biol. Chem. 265, 22075-22078[Abstract/Free Full Text]
  23. Nakagawa, T., Murakami, K., and Nakayama, K. (1993) FEBS Lett. 327, 165-171[CrossRef][Medline] [Order article via Infotrieve]
  24. Eipper, B. A., Park, L. P., Dickerson, I. M., Keutmann, H. T., Thiele, E. A., Rodriguez, H., Schofield, P. R., and Mains, R. E. (1987) Mol. Endocrinol. 1, 777-790[Abstract]
  25. Molloy, S. S., Thomas, L., VanSlyke, J. K., Stenberg, P. E., and Thomas, G. (1994) EMBO J. 13, 18-23[Abstract]
  26. Tausk, F. A., Milgram, S. L., Mains, R. E., and Eipper, B. A. (1992) Mol. Endocrinol. 6, 2185-2196[Abstract]
  27. Song, L., and Fricker, L. D. (1996) J. Biol. Chem. 271, 28884-28889[Abstract/Free Full Text]
  28. Klein, R. S., Das, B., and Fricker, L. D. (1992) J. Neurochem. 58, 2011-2018[Medline] [Order article via Infotrieve]
  29. Mitra, A., Song, L., and Fricker, L. D. (1994) J. Biol. Chem. 269, 19876-19881[Abstract/Free Full Text]
  30. Xu, H., and Shields, D. (1993) J. Cell Biol. 122, 1169-1184[Abstract]
  31. Ling, W. L. W., Siddhanta, A., and Shields, D. (1998) Methods (Orlando) 16, 141-149[CrossRef][Medline] [Order article via Infotrieve]
  32. Milgram, S. L., Johnson, R. C., and Mains, R. E. (1992) J. Cell Biol. 117, 717-728[Abstract]
  33. Austin, C. D., and Shields, D. (1996) J. Cell Biol. 135, 1471-1483[Abstract]
  34. Fricker, L. D., and Devi, L. (1993) J. Neurochem. 61, 1404-1415[Medline] [Order article via Infotrieve]
  35. Matlin, K., and Simons, K. (1983) Cell 34, 233-243[Medline] [Order article via Infotrieve]
  36. Chen, Y. G., Siddhanta, A., Austin, C. D., Hammond, S. M., Sung, T. C., Frohman, M. A., Morris, A. J., and Shields, D. (1997) J. Cell Biol. 138, 495-504[Abstract/Free Full Text]
  37. Martin, T. F., and Walent, J. H. (1989) J. Biol. Chem. 264, 10299-10308[Abstract/Free Full Text]
  38. Wan, L., Molloy, S. S., Thomas, L., Liu, G., Xiang, Y., Rybak, S. L., and Thomas, G. (1998) Cell 94, 205-216[Medline] [Order article via Infotrieve]
  39. Steiner, D. F., Smeekens, S. P., Ohagi, S., and Chan, S. J. (1992) J. Biol. Chem. 267, 23435-23438[Free Full Text]
  40. Parkinson, D. (1990) J. Biol. Chem. 265, 17101-17105[Abstract/Free Full Text]
  41. Fricker, L. D., and Devi, L. (1993) in Innovations in Proteases and Their Inhibitors (Aviles, F. X., ed), pp. 259-77, Walter de Gruyter & Co., Berlin
  42. Lippincott-Schwartz, J., Donaldson, J. G., Schweizer, A., Berger, E. G., Hauri, H. P., Yuan, L. C., and Klausner, R. D. (1990) Cell 60, 821-836[Medline] [Order article via Infotrieve]
  43. Chege, N., and Pfeffer, S. R. (1990) J. Cell Biol. 111, 893-899[Abstract]
  44. Bosshart, H., Humphrey, J., Deignan, E., Davidson, J., Drazba, J., Yuan, L., Oorschot, V., Peters, P. J., and Bonifacino, J. S. (1994) J. Cell Biol. 126, 1157-1166[Abstract]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.